On January 13, 2022, the Official Journal of the European Union reported that EU Commission issued REGULATION (EU) 2022/43 on renewing the approval of the active substance flumioxazin in accordance with Regulation (EC) No 1107/2009, and amending the Annexes to Commission Implementing Regulation (EU) No 540/2011 and to Implementing Regulation (EU) 2015/408. The expiration of approval on Flumioxazin (CAS No 103361-09-7, CIPAC No 578) is extended to 28 February 2037.

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. It shall apply from 1 March 2022.